Evidence map›Paper›PMID 29419429›Full record

ArticleHaematologica2018

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Anthony R Mato, Chadhi Nabhan, Meghan C Thompson, Nicole Lamanna, Danielle M Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D Cheson, Clive Zent and 16 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03816683 (Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life), which is not on this map. Cited by 249 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
249citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03816683 completednot on this mapstarted 2019, after this paper: background citation

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients With Mantle Cell Lymphoma Treated With Novel Agents

TypeobservationalSponsorAstraZenecaRan2019 to 2024Enrolled227ConditionsMantle Cell Lymphoma
3 · Its place in the literature

Who cites it

249 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

189 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Anthony R MatoHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA amato@mskcc.org.
Chadhi NabhanCardinal Health, Dublin, OH, USA.
Meghan C ThompsonHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Nicole LamannaHematology/Oncology, Presbyterian/Columbia University Medical Center, New York, NY, USA.
Danielle M BranderHematology/Oncology, Duke University, Durham, NC, USA.
Brian HillHematology and Medical Oncology, Cleveland Clinic, OH, USA.
Christina HowlettPharmacy, Ernest Mario School of Pharmacy, New Brunswick, NY, USA.
Alan SkarbnikHematology/Oncology, John Theurer Cancer Center, Hackensack, NY, USA.
Bruce D ChesonHematology/Oncology, Georgetown University Hospital, Washington DC, USA.
Clive ZentHematology/Oncology, University of Rochester Medical Center, NY, USA.
Jeffrey PuHematology/Oncology, Penn State Milton S Hershey Medical Center, PA, USA.
Pavel KiselevLymphoma, Celgene Corp, Summit, NY, USA.
Andre GoyHematology/Oncology, John Theurer Cancer Center, Hackensack, NY, USA.
David ClaxtonHematology/Oncology, Penn State Milton S Hershey Medical Center, PA, USA.
Krista IsaacHematology/Oncology, Lankenau Hospital, Wynnewood, PA, USA.
Kaitlin H KennardHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Colleen TimlinHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Daniel LandsburgHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Allison WinterHematology and Medical Oncology, Cleveland Clinic, OH, USA.
Sunita D NastaHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Spencer H BachowHematology/Oncology, Presbyterian/Columbia University Medical Center, New York, NY, USA.
Stephen J SchusterHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Colleen DorseyHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Jakub SvobodaHematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Paul BarrDivision of Hematology and Oncology, University of Rochester, NY, USA.
Chaitra S UjjaniHematology/Oncology, Georgetown University Hospital, Washington DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis of chronic lymphocytic leukemia patients treated with ibrutinib either commercially or on clinical trials. We aimed to compare the type and frequency of toxicities reported in either setting, assess discontinuation rates, and evaluate outcomes. This multicenter, retrospective analysis included ibrutinib-treated chronic lymphocytic leukemia patients at nine United States cancer centers or from the Connect® Chronic Lymphocytic Leukemia Registry. We examined demographics, dosing, discontinuation rates and reasons, toxicities, and outcomes. The primary endpoint was progression-free survival. Six hundred sixteen ibrutinib-treated patients were identified. A total of 546 (88%) patients were treated with the commercial drug. Clinical trial patients were younger (mean age 58

Indexed as

AdenineAdultAgedAged, 80 and overDisease ProgressionDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPiperidinesPrognosisProtein Kinase InhibitorsPyrazolesAdenineibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidines

Identifiers

PMID29419429
PMCPMC5927982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.